Agoracom: Small Cap Investment - Pluristem Life Systems, Inc. - MORE NEWS! PSTI SUBMITS FDA ORPHAN DRUG APP. FOR PLX PAD

patented technology to grow and expand adult Stem Cells

Adult stem cell development company commencing clinical trials applicable to estimated $30 billion degenerative disease market place

Reply New Message

Back To Forum List View

emma

Rank: Treasurer [?]

Points: 16214 [?]

Votes: 82 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

MORE NEWS! PSTI SUBMITS FDA ORPHAN DRUG APP. FOR PLX PAD

posted on Feb 20, 2014 08:14AM

Pluristem Therapeutics submits FDA orphan drug application for PLX-PAD
Pluristem Therapeutics announced it is submitting its application to the FDA requesting the company to be granted Orphan Drug Designation for its PLacental eXpanded, or PLX-PAD, cells in the treatment of severe preeclampsia. Pluristem has successfully received Orphan Drug Designation from the FDA for its PLX cells in two other indications: the treatment of aplastic anemia; and the treatment of Buerger's disease.

3 Recommendations

Reply New Message

Back To Forum List View

Please to post a reply